Literature DB >> 9584558

Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial.

J Pater1, D Osoba, B Zee, W Lofters, M Gore, E Dempsey, M Palmer, C Chin.   

Abstract

Previous studies conducted by our group suggested that the ability to demonstrate an impact of emesis control on quality of life might depend upon when an quality of life instrument was administered in relation to chemotherapy and on the time frame of the questionnaire. This study was conducted to address this issue. Six hundred and fifty patients receiving moderately emetogenic chemotherapy in a randomized trial comparing a variety of anti-emetic regimens were allocated to four different modes of administration (days 4 and 8; 3 and 7 day time frames) of the QLQ-C30. Patients who completed the questionnaire at the time of maximal impact of chemotherapy (day 3) were more likely to report deterioration in quality of life. Patients who completed questionnaires at day 8 were more likely to report deterioration in quality of life if their questionnaire had a 7 day time frame rather than a 3 day time frame. Patients receiving more effective anti-emetic therapy had better quality of life. It was concluded that better anti-emetic control improves quality of life after moderately emetogenic chemotherapy. In studying quality of life in situations where the impact of treatment waxes and wanes, careful attention needs to be paid to scheduling the administration of questionnaires and to their time frame.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9584558     DOI: 10.1023/a:1024954518241

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  9 in total

1.  Quality of life studies in chemotherapy-induced emesis.

Authors:  D Osoba; B Zee; D Warr; L Kaizer; J Latreille; J Pater
Journal:  Oncology       Date:  1996-06       Impact factor: 2.935

2.  Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  D Osoba; B Zee; D Warr; J Latreille; L Kaizer; J Pater
Journal:  Support Care Cancer       Date:  1997-07       Impact factor: 3.603

3.  Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

Authors:  W S Lofters; J L Pater; B Zee; E Dempsey; D Walde; J P Moquin; K Wilson; P Hoskins; R M Guevin; S Verma; R Navari; J E Krook; J Hainsworth; M Palmer; C Chin
Journal:  J Clin Oncol       Date:  1997-08       Impact factor: 44.544

Review 4.  Methodology of antiemetic trials: a review.

Authors:  M Tonato; F Roila; A Del Favero
Journal:  Ann Oncol       Date:  1991-02       Impact factor: 32.976

5.  The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

Authors:  J L Pater; W S Lofters; B Zee; E Dempsey; D Walde; J P Moquin; K Wilson; P Hoskins; R M Guevin; S Verma; R Navari; J E Krook; J Hainsworth; M Palmer; C Chin
Journal:  Ann Oncol       Date:  1997-02       Impact factor: 32.976

6.  Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  D Osoba; B Zee; J Pater; D Warr; J Latreille; L Kaizer
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

7.  Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.

Authors:  L Kaizer; D Warr; P Hoskins; J Latreille; W Lofters; J Yau; M Palmer; B Zee; M Levy; J Pater
Journal:  J Clin Oncol       Date:  1994-05       Impact factor: 44.544

8.  Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy.

Authors:  J Latreille; D Stewart; F Laberge; P Hoskins; J Rusthoven; E McMurtrie; D Warr; L Yelle; D Walde; F Shepherd
Journal:  Support Care Cancer       Date:  1995-09       Impact factor: 3.603

9.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

  9 in total
  7 in total

1.  Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients.

Authors:  D E Ediebah; C Coens; J T Maringwa; C Quinten; E Zikos; J Ringash; M King; C Gotay; H-H Flechtner; J Schmucker von Koch; J Weis; E F Smit; C-H Köhne; A Bottomley
Journal:  Ann Oncol       Date:  2012-08-30       Impact factor: 32.976

2.  Development, feasibility and compliance of a web-based system for very frequent QOL and symptom home self-assessment after hematopoietic stem cell transplantation.

Authors:  N Bush; G Donaldson; C Moinpour; M Haberman; D Milliken; V Markle; J Lauson
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

3.  The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer.

Authors:  G Rodrigues; A Bezjak; D Osoba; P Catton; D Tsuji; D Taylor; P Warde
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

4.  Quality of life of breast cancer patients in the course of adjuvant radiotherapy.

Authors:  K Budischewski; S Fischbeck; St Mose
Journal:  Support Care Cancer       Date:  2007-08-07       Impact factor: 3.603

Review 5.  Health-related quality of life in patients with brain tumors: limitations and additional outcome measures.

Authors:  Linda Dirven; Jacob C Reijneveld; Neil K Aaronson; Andrew Bottomley; Bernard M J Uitdehaag; Martin J B Taphoorn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

Review 6.  Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy.

Authors:  Enzo Ballatori; Fausto Roila
Journal:  Health Qual Life Outcomes       Date:  2003-09-17       Impact factor: 3.186

7.  Assessing quality of life on the day of chemotherapy administration underestimates patients' true symptom burden.

Authors:  Johannes M Giesinger; Lisa M Wintner; August Zabernigg; Eva-Maria Gamper; Anne S Oberguggenberger; Monika J Sztankay; Georg Kemmler; Bernhard Holzner
Journal:  BMC Cancer       Date:  2014-10-10       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.